Molecular therapy in support to radiotherapy

Mutation Research - Reviews in Mutation Research

Volumn 704, Issue 1-3, 2010, Pages 182-189

  Dutreix, M ^a   Cosset, J M ^a   Sun, J S ^b,c  

^a INSTITUT CURIE   (France)

^b DNA Therapeutics   (France)

^c MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Molecular therapy; Oligonucleotides; Radiotherapy; shRNA; siDNA; siRNA

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; CEREPRO; CETUXIMAB; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GENCIDINE; GLIATAK; IBRITUMOMAB TIUXETAN; IODINE 131; KU ANTIGEN; LERAFAON; OLIGONUCLEOTIDE; ONYX 015; PANCATAK; PEROXIREDOXIN 1; PROSTATAK; PROTEIN P53; RAD51 PROTEIN; RAD54 PROTEIN; RAF PROTEIN; RIBONUCLEASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; THYMIDINE KINASE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL; COLON CANCER; CPG ISLAND; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME DEGRADATION; ESOPHAGUS CANCER; EXCISION REPAIR; FIBROSARCOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; IMMUNOSTIMULATION; LUNG NON SMALL CELL CANCER; MELANOMA; MICROENVIRONMENT; MOLECULAR THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN TARGETING; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SUICIDE GENE THERAPY; THYROID TUMOR; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA REPAIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING;

EID: 77951977223     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2010.01.001     Document Type: Review

References (94)

1. Elshaikh M., Ljungman M., Ten Haken R., and Lichter A.S. Advances in radiation oncology. Annu. Rev. Med. 57 (2006) 19-31
2. Kruh G.D. Introduction to resistance to anticancer agents. Oncogene 22 (2003) 7262-7264
3. Perona R., and Sanchez-Perez I. Control of oncogenesis and cancer therapy resistance. Br. J. Cancer 90 (2004) 573-577
4. Liu S.K., Olive P.L., and Bristow R.G. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev. 27 (2008) 445-458
5. Powell S.N., and Bindra R.S. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 8 (2009) 1153-1165
6. Bouard D., Alazard-Dany D., and Cosset F.L. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 157 (2009) 153-165
7. Galanis E., Vile R., and Russell S.J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38 (2001) 177-192
8. Worgall S., Wolff G., Falck-Pedersen E., and Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8 (1997) 37-44
9. Crooke S.T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489 (1999) 31-44
10. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489 (1999) 141-158
11. Nielsen P.E. Antisense peptide nucleic acids. Curr. Opin. Mol. Ther. 2 (2000) 282-287
12. Kauppinen S., Vester B., and Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb. Exp. Pharmacol. (2006) 405-422
13. Lebleu B., Moulton H.M., Abes R., Ivanova G.D., Abes S., Stein D.A., Iversen P.L., Arzumanov A.A., and Gait M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60 (2008) 517-529
14. Cheng J.C., Moore T.B., and Sakamoto K.M. RNA interference and human disease. Mol. Genet. Metab. 80 (2003) 121-128
15. Scherer L., and Rossi J.J. Recent applications of RNAi in mammalian systems. Curr. Pharm. Biotechnol. 5 (2004) 355-360
16. Scherr M., Morgan M.A., and Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. 10 (2003) 245-256
17. Lu P.Y., Xie F., and Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 54 (2005) 117-142
18. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
19. Vollmer J., and Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61 (2009) 195-204
20. Mason K.A., Ariga H., Neal R., Valdecanas D., Hunter N., Krieg A.M., Whisnant J.K., and Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. 11 (2005) 361-369
21. Meng Y., Carpentier A.F., Chen L., Boisserie G., Simon J.M., Mazeron J.J., and Delattre J.Y. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 116 (2005) 992-997
22. Quanz M., Chassoux D., Berthault N., Agrario C., Sun J.S., and Dutreix M. Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response. PLoS One 4 (2009) e6298
23. Quanz M., Berthault N., Roulin C., Roy M., Herbette A., Agrario C., Alberti C., Josserand V., Coll J.L., Sastre-Garau X., Cosset J.M., Larue L., Sun J.S., and Dutreix M. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin. Cancer Res. 15 (2009) 1308-1316
24. Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12 (2002) 103-128
25. Jeong J.H., Mok H., Oh Y.K., and Park T.G. siRNA conjugate delivery systems. Bioconjug. Chem. 20 (2009) 5-14
26. Juliano R., Alam M.R., Dixit V., and Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36 (2008) 4158-4171
27. Akhtar S., and Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59 (2007) 164-182
28. Gao K., and Huang L. Nonviral methods for siRNA delivery. Mol. Pharm. 6 (2009) 651-658
29. Juliano R., Bauman J., Kang H., and Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6 (2009) 686-695
30. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006) 219-234
31. Townsend D.M., and Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22 (2003) 7369-7375
32. Helleday T., Petermann E., Lundin C., Hodgson B., and Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer (2008)
33. Mauceri H.J., Beckett M.A., Liang H., Sutton H.G., Pitroda S., Galka E., Efimova E., Darga T., Khodarev N.N., King C.R., Posner M.C., Hellman S., Kufe D.W., and Weichselbaum R.R. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 16 (2009) 373-381
34. Mauceri H.J., Hanna N.N., Wayne J.D., Hallahan D.E., Hellman S., and Weichselbaum R.R. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56 (1996) 4311-4314
35. Zimmerman R.J., Marafino Jr. B.J., Chan A., Landre P., and Winkelhake J.L. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. J. Immunol. 142 (1989) 1405-1409
36. Hallahan D.E., Beckett M.A., Kufe D., and Weichselbaum R.R. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 19 (1990) 69-74
37. Gridley D.S., Glisson W.C., and Uhm J.R. Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Ther. Immunol. 1 (1994) 25-31
38. Azria D., Dorvillius M., Gourgou S., Martineau P., Robert B., Pugniere M., Delard R., Ychou M., Dubois J.B., and Pelegrin A. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 1363-1373
39. Sersa G., Willingham V., and Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 42 (1988) 129-134
40. Gridley D.S., Hammond S.N., and Slater J.M. Effects of radiolabelled murine antibody infusion on TNF-alpha, IL-1 beta, and soluble IL-2 receptor in cancer patients. J. Clin. Lab. Anal. 8 (1994) 223-227
41. Nishiguchi I., Willingham V., and Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 18 (1990) 555-558
42. Weichselbaum R.R., and Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 16 (2009) 609-619
43. Zhang B., Wang Y., and Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett. (2009)
44. Chang J.W., Jeon H.B., Lee J.H., Yoo J.S., Chun J.S., Kim J.H., and Yoo Y.J. Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 289 (2001) 507-512
45. Kim H.J., Chae H.Z., Kim Y.J., Kim Y.H., Hwangs T.S., Park E.M., and Park Y.M. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol. Toxicol. 19 (2003) 285-298
46. Alfonso P., Catala M., Rico-Morales M.L., Durante-Rodriguez G., Moro-Rodriguez E., Fernandez-Garcia H., Escribano J.M., Alvarez-Fernandez E., and Garcia-Poblete E. Proteomic analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue. Proteomics 4 (2004) 442-447
47. Lehtonen S.T., Svensk A.M., Soini Y., Paakko P., Hirvikoski P., Kang S.W., Saily M., and Kinnula V.L. Peroxiredoxins a novel protein family in lung cancer. Int. J. Cancer 111 (2004) 514-521
48. Zhang B., Wang Y., Liu K., Yang X., Song M., and Bai Y. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem. Pharmacol. 75 (2008) 660-667
49. Spitzweg C., Dietz A.B., O'Connor M.K., Bergert E.R., Tindall D.J., Young C.Y., and Morris J.C. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8 (2001) 1524-1531
50. Hakkarainen T., Rajecki M., Sarparanta M., Tenhunen M., Airaksinen A.J., Desmond R.A., Kairemo K., and Hemminki A. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin. Cancer Res. (2009)
51. Lai S.Y., Koppikar P., Thomas S.M., Childs E.E., Egloff A.M., Seethala R.R., Branstetter B.F., Gooding W.E., Muthukrishnan A., Mountz J.M., Lui V.W., Shin D.M., Agarwala S.S., Johnson R., Couture L.A., Myers E.N., Johnson J.T., Mills G., Argiris A., and Grandis J.R. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J. Clin. Oncol. 27 (2009) 1235-1242
52. Kasid U., Pfeifer A., Brennan T., Beckett M., Weichselbaum R.R., Dritschilo A., and Mark G.E. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243 (1989) 1354-1356
53. Gokhale P.C., Soldatenkov V., Wang F.H., Rahman A., Dritschilo A., and Kasid U. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 4 (1997) 1289-1299
54. Gokhale P.C., McRae D., Monia B.P., Bagg A., Rahman A., Dritschilo A., and Kasid U. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 9 (1999) 191-201
55. Soldatenkov V.A., Dritschilo A., Wang F.H., Olah Z., Anderson W.B., and Kasid U. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J. Sci. Am. 3 (1997) 13-20
56. Dritschilo A., Huang C.H., Rudin C.M., Marshall J., Collins B., Dul J.L., Zhang C., Kumar D., Gokhale P.C., Ahmad A., Ahmad I., Sherman J.W., and Kasid U.N. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12 (2006) 1251-1259
57. Li H., Liu T., and Wang Z. Gene therapy of human pancreatic carcinoma by recombinant retroviral vector expressing herpes simplex virus thymidine kinase gene. Zhonghua Bing Li Xue Za Zhi 24 (1995) 345-347
58. Ido A., Nakata K., Kato Y., Nakao K., Murata K., Fujita M., Ishii N., Tamaoki T., Shiku H., and Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55 (1995) 3105-3109
59. Kim S.H., Kim J.H., Kolozsvary A., Brown S.L., and Freytag S.O. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. J. Neurooncol. 33 (1997) 189-194
60. Teh B.S., Aguilar-Cordova E., Kernen K., Chou C.C., Shalev M., Vlachaki M.T., Miles B., Kadmon D., Mai W.Y., Caillouet J., Davis M., Ayala G., Wheeler T., Brady J., Carpenter L.S., Lu H.H., Chiu J.K., Woo S.Y., Thompson T., and Butler E.B. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 605-613
61. Chen Y., DeWeese T., Dilley J., Zhang Y., Li Y., Ramesh N., Lee J., Pennathur-Das R., Radzyminski J., Wypych J., Brignetti D., Scott S., Stephens J., Karpf D.B., Henderson D.R., and Yu D.C. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61 (2001) 5453-5460
62. Tetzlaff M.T., Teh B.S., Timme T.L., Fujita T., Satoh T., Tabata K., Mai W.Y., Vlachaki M.T., Amato R.J., Kadmon D., Miles B.J., Ayala G., Wheeler T.M., Aguilar-Cordova E., Thompson T.C., and Butler E.B. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol. Cancer Res. Treat. 5 (2006) 23-36
63. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62 (2002) 4968-4976
64. Freytag S.O., Stricker H., Peabody J., Pegg J., Paielli D., Movsas B., Barton K.N., Brown S.L., Lu M., and Kim J.H. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 15 (2007) 636-642
65. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 3 (2008) 27-32
66. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
67. Mason K.A., Neal R., Hunter N., Ariga H., Ang K., and Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother. Oncol. 80 (2006) 192-198
68. Carpentier A., Laigle-Donadey F., Zohar S., Capelle L., Behin A., Tibi A., Martin-Duverneuil N., Sanson M., Lacomblez L., Taillibert S., Puybasset L., Van Effenterre R., Delattre J.Y., and Carpentier A.F. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 8 (2006) 60-66
69. Tribius S., Pidel A., and Casper D. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 511-523
70. Masuda K., Aramaki R., Takaki T., and Wakisaka S. Possible explanation of radioresistance of glioblastoma in situ. Int. J. Radiat. Oncol. Biol. Phys. 9 (1983) 255-258
71. Kauffmann A., Rosselli F., Lazar V., Winnepenninckx V., Mansuet-Lupo A., Dessen P., van den Oord J.J., Spatz A., and Sarasin A. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27 (2008) 565-573
72. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., Ismail S., Stevens C., and Meyn R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11 (2005) 4912-4922
73. Plummer E.R., Middleton M.R., Jones C., Olsen A., Hickson I., McHugh P., Margison G.P., McGown G., Thorncroft M., Watson A.J., Boddy A.V., Calvert A.H., Harris A.L., Newell D.R., and Curtin N.J. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res. 11 (2005) 3402-3409
74. Rass K., and Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol. 624 (2008) 162-178
75. Fischer U., and Meese E. Glioblastoma multiforme: the role of DSB repair between genotype and phenotype. Oncogene 26 (2007) 7809-7815
76. Inoue R., Isono M., Abe M., Abe T., and Kobayashi H. A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma. Neurol. Res. 25 (2003) 875-879
77. Chen G.G., Sin F.L., Leung B.C., Ng H.K., and Poon W.S. Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death. J. Cell. Physiol. 203 (2005) 127-132
78. Ruan S., Okcu M.F., Ren J.P., Chiao P., Andreeff M., Levin V., and Zhang W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res. 58 (1998) 1538-1543
79. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., and Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 7 (2005) 1044-1052
80. Yu D., Sekine E., Fujimori A., Ochiya T., and Okayasu R. Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. Cancer Sci. 99 (2008) 810-815
81. Nimura Y., Kawata T., Uzawa K., Okamura J., Liu C., Saito M., Shimada H., Seki N., Nakagawara A., Ito H., Ochiai T., and Tanzawa H. Silencing Ku80 using small interfering RNA enhanced radiation sensitivity in vitro and in vivo. Int. J. Oncol. 30 (2007) 1477-1484
82. Li G.C., He F., Shao X., Urano M., Shen L., Kim D., Borrelli M., Leibel S.A., Gutin P.H., and Ling C.C. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res. 63 (2003) 3268-3274
83. Wang D., Xiang D.B., Yang X.Q., Chen L.S., Li M.X., Zhong Z.Y., and Zhang Y.S. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer (2009)
84. Xiang D.B., Chen Z.T., Wang D., Li M.X., Xie J.Y., Zhang Y.S., Qing Y., Li Z.P., and Xie J. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther. 15 (2008) 625-635
85. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13 (2007) 1383-1388
86. Trofimova I., Dimtchev A., Jung M., Rosenthal D., Smulson M., Dritschilo A., and Soldatenkov V. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. Cancer Res. 62 (2002) 6879-6883
87. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 (2005) 1016-1027
88. Edelman J., and Nemunaitis J. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr. Opin. Mol. Ther. 5 (2003) 611-617
89. Kakinuma H., Bergert E.R., Spitzweg C., Cheville J.C., Lieber M.M., and Morris J.C. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 63 (2003) 7840-7844
90. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R., Langford G., Murray N., and Yla-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10 (2004) 967-972
91. Trask T.W., Trask R.P., Aguilar-Cordova E., Shine H.D., Wyde P.R., Goodman J.C., Hamilton W.J., Rojas-Martinez A., Chen S.H., Woo S.L., and Grossman R.G. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1 (2000) 195-203
92. Miles B.J., Shalev M., Aguilar-Cordova E., Timme T.L., Lee H.M., Yang G., Adler H.L., Kernen K., Pramudji C.K., Satoh T., Gdor Y., Ren C., Ayala G., Wheeler T.M., Butler E.B., Kadmon D., and Thompson T.C. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12 (2001) 1955-1967
93. Murad Y.M., Clay T.M., Lyerly H.K., and Morse M.A. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol. Ther. 7 (2007) 1257-1266
94. He F., Li L., Kim D., Wen B., Deng X., Gutin P.H., Ling C.C., and Li G.C. Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res. 67 (2007) 634-642